BeStock  

MiniMed Group MMED

US equityMarket cap rank #2130Medical Instruments & Supplies
$16.01 −$0.25 (-1.54%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $16.21 +1.25%
Open$16.08
Prev close$16.26
Day range$15.92 – $16.79
Volume4.58M
Market cap$4.50B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q1, ended Jul 2026

Revenue$843.00M+16.6% YoY
Operating profit$2.00M-33.3% YoY
Net profit$0.00+100.0% YoY
Diluted EPS$0.00+100.0% YoY
Free cash flow-$90.00M+53.6% YoY
Operating cash flow-$49.00M

Revenue, last 7 quarters

$687.0MJan '25$724.0MApr '25$723.0MJul '25$752.0MOct '25$790.0MJan '26$837.0MApr '26$843.0MJul '26

Net profit, last 7 quarters

$-7.0MJan '25$-168.0MApr '25$-16.0MJul '25$-30.0MOct '25$-111.0MJan '26$-185.0MApr '26$0.0Jul '26

Diluted EPS by quarter

-0.04Jan '25-0.61Apr '25-0.07Jul '25-0.10Oct '25-0.42Jan '26-0.66Apr '260.00Jul '26

Free cash flow by quarter

$-26.0MJan '25$26.0MApr '25$-194.0MJul '25$-13.0MOct '25$13.0MJan '26$-226.0MApr '26$-90.0MJul '26

Annual revenue

$2.2BFY23$2.5BFY24$2.7BFY25$3.1BFY26

Profitability & balance sheet

Gross margin53.9%
Operating margin-5.0%
Net margin-9.7%
Return on equity-8.7%
Return on assets-6.7%
Return on invested capital-8.7%
Current ratio1.81
Liabilities / assets23.3%
Cash & investments$207.00M
Net cash (debt)$207.00M

Where the revenue comes from

Quarter 2027/Q1

By business line

  • Continuous glucose monitoring (CGM)$431.00M 51.1%
  • Consumables$261.00M 31.0%
  • Pumps$144.00M 17.1%
  • Other$7.00M 0.8%

Balance sheet

Line item 2027 Q1 2026 ANNUAL 2026 Q4 2026 Q3 2026 Q2
Stockholders' Equity $3.62B $3.61B $3.61B $3.46B $3.74B
Other Non-Current Assets $152.00M $147.00M $147.00M $146.00M $150.00M
-Other Intangible Assets $99.00M $106.00M $106.00M $112.00M $119.00M
-Goodwill $2.26B $2.26B $2.26B $2.26B $2.26B
Goodwill and Other Intangible Assets $2.35B $2.36B $2.36B $2.37B $2.38B
Non Current Accounts Receivables $58.00M $61.00M $61.00M $19.00M $64.00M
Net PPE $736.00M $711.00M $711.00M $701.00M $755.00M
Total Non-Current Assets $3.30B $3.28B $3.28B $3.23B $3.34B
Other Current Assets $72.00M $54.00M $54.00M $38.00M $13.00M
Inventory $356.00M $341.00M $341.00M $407.00M $362.00M
-Due from Related Parties Current $602.00M $455.00M $455.00M – –
-Accounts Receivable $180.00M $200.00M $200.00M $653.00M $166.00M
Total Liabilities $1.10B $1.02B $1.02B $880.00M $491.00M
Total Current Liabilities $782.00M $702.00M $702.00M $696.00M $350.00M
Total Equity $3.62B $3.61B $3.61B $3.46B $3.74B
Other Non-Current Liabilities $316.00M $317.00M $317.00M $184.00M $141.00M
Total Non-Current Liabilities $316.00M $317.00M $317.00M $184.00M $141.00M
Other Current Liabilities -$1.00M $1.00M $1.00M -$1.00M -$1.00M
Current Deferred Liabilities $14.00M $15.00M $15.00M $13.00M –
-Current Capital Lease Obligation $9.00M $8.00M $8.00M $11.00M –
Current Accrued Expenses $129.00M $177.00M $177.00M $186.00M $128.00M
-Due to Related Parties Current $178.00M – – – –
-Total Tax Payable $76.00M $38.00M $38.00M – –
-Accounts Payable $251.00M $163.00M $163.00M $303.00M $129.00M
Payables $505.00M $201.00M $201.00M $303.00M $129.00M
Receivables $782.00M $655.00M $655.00M $653.00M $166.00M
-Cash and Cash Equivalents $207.00M $298.00M $298.00M $10.00M $350.00M
Cash and Cash Equivalents & Short-Term Investments $207.00M $298.00M $298.00M $10.00M $350.00M
Total Current Assets $1.42B $1.35B $1.35B $1.11B $891.00M
Total Assets $4.72B $4.63B $4.63B $4.34B $4.24B
Capital Stock $3.00M $3.00M $3.00M – $3.00M
-Common Stock $3.00M $3.00M $3.00M – $3.00M
-Preferred Stock $0.00 $0.00 $0.00 – –
Retained Earnings -$116.00M -$116.00M -$116.00M – -$5.00M
Short-Term Debt and Capital Lease Obligation $9.00M $145.00M $145.00M $11.00M –
Gains/Losses Not Affecting Retained Earnings -$14.00M -$12.00M -$12.00M $14.00M $8.00M
Additional Paid-In Capital $3.75B $3.74B $3.74B – $3.74B
-Accumulated Depreciation – -$781.00M -$781.00M – –
-Gross PPE – $1.49B $1.49B – –
Minority Interests – $0.00 $0.00 – –
-Current Debt – $137.00M $137.00M – –
Other Equity Interests – – – $3.45B –

Cash flow

Line item 2027 Q1 2026 Q4 2026 ANNUAL 2026 Q3 2026 Q2
-Change in Payables and Accrued Expense $78.00M $204.00M $178.00M $126.00M $19.00M
-Change in Inventory -$15.00M $64.00M -$29.00M -$43.00M -$20.00M
-Change in Receivables -$148.00M -$444.00M -$538.00M -$74.00M -$15.00M
Change in Working Capital -$110.00M $12.00M -$166.00M $22.00M -$12.00M
Other Non-Cash Items $2.00M $3.00M $19.00M $4.00M $2.00M
Deferred Tax $2.00M -$55.00M -$54.00M – –
Depreciation & Depletion & Amortization $41.00M $39.00M $156.00M $39.00M $39.00M
Net Income from Continuing Operations $0.00 -$185.00M -$317.00M -$111.00M -$5.00M
Net cash flow from continuing operations -$50.00M -$171.00M -$197.00M $67.00M $47.00M
Operating Cash Flow -$49.00M -$170.00M -$197.00M $66.00M $48.00M
-Change In Other Working Capital -$25.00M $31.00M $66.00M $13.00M $4.00M
Net cash flow from investing -$41.00M -$56.00M -$233.00M -$53.00M -$61.00M
Free Cash Flow -$90.00M -$226.00M -$420.00M $13.00M -$13.00M
Effect of Exchange Rate Changes -$1.00M – $1.00M – –
Beginning Cash Balance $298.00M $10.00M $11.00M $8.00M $9.00M
Net Change in Cash -$90.00M $287.00M $286.00M $2.00M -$1.00M
Ending Cash Balance $207.00M $298.00M $298.00M $10.00M $8.00M
Net Cash Flow from Continuing Financing Activities $0.00 $512.00M $716.00M -$11.00M $13.00M
Financing Cash Flow $0.00 $512.00M $716.00M -$11.00M $13.00M
Net PPE Purchase and Sale -$41.00M -$56.00M -$223.00M -$53.00M -$61.00M
Net Cash Flow from Continuing Investing Activities -$41.00M -$56.00M -$233.00M -$53.00M -$61.00M
Net Other Investing Changes – $0.00 -$10.00M $0.00 $0.00
Net Other Financing Charges – -$26.00M $178.00M -$11.00M $13.00M
Gain/Loss from Continuing Operations – $1.00M $7.00M $2.00M $2.00M
-Change in Other Current Liabilities – – $157.00M – –
Net Common Stock Issuance – – $538.00M – –
Net Investment Purchase and Sale – – $0.00 – –

Income statement

Line item 2027 Q1 2026 ANNUAL 2026 Q4 2026 Q3 2026 Q2
Basic EPS $0.00 -$1.30 -$0.66 -$0.42 -$0.10
Net Income to Parent Company $0.00 -$333.00M -$185.00M -$119.00M -$27.00M
Net Income to Common Stockholders $0.00 -$333.00M -$185.00M -$119.00M -$27.00M
Diluted EPS $0.00 -$1.30 -$0.66 -$0.42 -$0.10
Minority Interests $0.00 $16.00M $0.00 $8.00M -$3.00M
Profit from Continuing Operations $0.00 -$317.00M -$185.00M -$111.00M -$31.00M
Net Profit $0.00 -$317.00M -$185.00M -$111.00M -$30.00M
Tax $4.00M $128.00M $93.00M $12.00M $19.00M
Pretax Profit $4.00M -$189.00M -$92.00M -$99.00M -$12.00M
-Less:Other Special Charges -$2.00M $18.00M $7.00M -$6.00M $0.00
Operating Expense $463.00M $1.84B $567.00M $455.00M $438.00M
Cost of Revenue $378.00M $1.42B $357.00M $428.00M $324.00M
Total Operating Revenue $843.00M $3.10B $837.00M $790.00M $752.00M
Total Revenue as Reported $843.00M $3.10B $837.00M $790.00M $752.00M
Special Income (Charges) $2.00M -$31.00M -$6.00M -$7.00M $0.00
Gross Profit $465.00M $1.68B $480.00M $362.00M $428.00M
Selling and Admin Expenses $312.00M $1.18B $299.00M $309.00M $318.00M
Research & Development $115.00M $448.00M $99.00M $114.00M $111.00M
Other Income (Expense) $2.00M -$30.00M -$5.00M -$7.00M -$1.00M
Operating Profit $2.00M -$159.00M -$87.00M -$93.00M -$10.00M
Other Operating Expenses $36.00M $208.00M $169.00M $32.00M $9.00M
-Selling & Marketing Expense – $1.18B $299.00M $309.00M –
Other Non-Operating Income (Expenses) – $1.00M – – –
-Less:Restructuring and Mergern & Acquisition – $13.00M -$1.00M $13.00M –

Discussion

No comments yet — be the first to weigh in on MMED.

Sign in to join the discussion.

Scroll to Top